Aaron Wealth Advisors LLC Sells 72 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Aaron Wealth Advisors LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,114 shares of the pharmaceutical company’s stock after selling 72 shares during the period. Aaron Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,254,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $27,000. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth $35,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $422.00 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The business’s fifty day moving average is $440.94 and its 200 day moving average is $466.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on VRTX. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. Truist Financial cut their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.